Using 5T MRI and Metabolomics to Predict Hemorrhage Risk in Moyamoya Disease A Prospective Observational Cohort Study

What This Trial Is About

Researchers are studying patients with moyamoya disease MMD, a rare condition causing narrowing or blockage of brain arteries and formation of fragile collateral vessels. The study aims to develop a new model to predict the risk of brain hemorrhage, a leading cause of death and disability in MMD, by using advanced 5.0T MRI imaging combined with metabolomic biomarkers and clinical data. This research hopes to help identify high-risk patients early for timely treatment. Participants will undergo a detailed 5.0T MRI brain scan using multiple imaging techniques to assess blood vessels and brain tissue. Blood and urine samples will be collected for metabolomic analysis, and artery tissue samples from surgery may be studied to validate findings. Patients will be grouped by initial symptoms hemorrhagic or ischemic types and followed for 12 months to monitor new brain hemorrhage events. During the 12-month follow-up, participants will have clinical assessments and imaging to detect new hemorrhages. Researchers will analyze MRI features, blood flow dynamics, metabolomic profiles, and clinical information using machine learning to create a risk prediction system. This approach aims to improve early detection of hemorrhage risk and guide surgical decisions, potentially reducing disability and death from MMD-related stroke.

5T MRI and Metabolomics-Based Hemorrhage Risk Prediction in Moyamoya Disease